陈松文,刘少稳

• 1:上海市第一人民医院心内科

摘要(Abstract)：

<正>卒中是心房颤动(房颤,atrial fibrillation,AF)最危险而严重的并发症。抗凝治疗可以显著降低房颤患者的卒中风险,改善预后,因而成为房颤治疗的核心策略之一。在抗凝药物的选择上,新型口服抗凝药物(new oral anticoagulants,NOAC)包括直接凝血酶抑制药(达比加群酯)和Ⅹa因子抑制药(阿哌沙

关键词(KeyWords)： 新型口服抗凝药物;心房颤动;介入治疗

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 陈松文,刘少稳

参考文献(References)：

• [1]Weitz JI,Eikelboom JW,Samama MM.New antithrombotic drugs:Antithrombotic Therapy and Prevention of Thrombosis,9th ed:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest,2012,141(2 Suppl):e120Se151S.
• [2]January CT,Wann LS,Alpert JS,et al.2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation:executive summary:a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.Circulation,2014,130(23):2071-2104.
• [3]Bushnell C,Mc Cullough LD,Awad IA,et al.Guidelines for the prevention of stroke in women:a statement for healthcare professionals from the American Heart Association/American Stroke Association.Stroke,2014,45(5):1545-1588.
• [4]Camm AJ,Lip GY,De Caterina R,et al.2012 focused update of the ESC Guidelines for the management of atrial fibrillation:an update of the 2010 ESC Guidelines for the management of atrial fibrillation.Developed with the special contribution of the European Heart Rhythm Association.Eur Heart J,2012,33(21):2719-2747.
• [5]Heidbuchel H,Verhamme P,Alings M,et al.European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.Europace,2013,15(5):625-651.
• [6]Heidbuchel H,Verhamme P,Alings M,et al.Updated European Heart Rhythm Association Practical Guide on the use of nonvitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.Europace,2015,17(10):1467-1507.
• [7]Eikelboom JW,Connolly SJ,Brueckmann M,et al.Dabigatran versus warfarin in patients with mechanical heart valves.N Engl J Med,2013,369(13):1206-1214.
• [8]Van de Werf F,Brueckmann M,Connolly SJ,et al.A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves:THE Randomized,phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement(RE-ALIGN).Am Heart J,2012,163(6):931-937.
• [9]Nieuwlaat R,Capucci A,Camm AJ,et al.Atrial fibrillation management:a prospective survey in ESC member countries:the Euro Heart Survey on Atrial Fibrillation.Eur Heart J,2005,26(22):2422-2434.
• [10]Kirchhof P,Ammentorp B,Darius H,et al.Management of atrial fibrillation in seven European countries after the publication of the2010 ESC Guidelines on atrial fibrillation:primary results of the PREvention o F thromboemolic events--European Registry in Atrial Fibrillation(PREFER in AF).Europace,2014,16(1):6-14.
• [11]Breithardt G,Baumgartner H,Berkowitz SD,et al.Clinical characteristics and outcomes with rivaroxaban vs.warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial.Eur Heart J,2014,35(47):3377-3385.
• [12]Di Pasquale G,Zagnoni S,Riva L.Novel oral anticoagulants and valvular atrial fibrillation:are they always contraindicated?.Intern Emerg Med,2015,10(1):21-24.
• [13]Avezum A,Lopes RD,Schulte PJ,et al.Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease:findings from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation(ARISTOTLE)trial.Circulation,2015,132(8):624-632.
• [14]佟佳宾,施海峰,邹彤,等.高龄心房颤动患者导管消融围术期不同抗凝方案的对比观察.中国介入心脏病学杂志,2014,22(4):220-224.
• [15]Chiang CE,Wang KL,Lip GY.Stroke prevention in atrial fibrillation:an Asian perspective.Thromb Haemost,2014,111(5):789-797.
• [16]Apostolakis S,Sullivan RM,Olshansky B,et al.Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin:the SAMe-TT2R2score.Chest,2013,144(5):1555-1563.
• [17]Ruiz-Ortiz M,Bertomeu V,Cequier A,et al.Validation of the SAMe-TT2R2score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists.Thromb Haemost,2015,114(4):695-701.
• [18]Abumuaileq RR,Abu-Assi E,Raposeiras-Roubin S,et al.Evaluation of SAMe-TT2R2risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with nonvalvular atrial fibrillation on vitamin-K antagonists.Europace,2015,17(5):711-717.
• [19]Eikelboom JW,Quinlan DJ,van Ryn J,et al.Idarucizumab:the antidote for reversal of dabigatran.Circulation,2015,132(25):2412-2422.
• [20]Bruness CB.Idarucizumab:first global approval.Drugs,2015,75(18):2155-2161.
• [21]Thibault N,Morrill AM,Willett KC.Idarucizumab for reversing dabigatran-induced anticoagulation:a systematic review.Am J Ther,2016.[Epub ahead of print]